Thomas Amidon, MD
Cardiovascular Disease · Bellevue, WANPI 1699736579
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $46,167 of the $64,269 with a category attached, or 71.8%. 25 manufacturers reported payments, led by Sanofi-aventis U.S. LLC at 29.6% of the total. Reporting peaked in 2019 at $36,048 and has fallen 98.6% since, to $495 in 2025. Among cardiovascular disease clinicians in WA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 145 payments — averaging $443.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi-aventis U.S. LLC$19K
- Regeneron Healthcare Solutions, Inc.$13K
- Siemens Medical Solutions USA, Inc.$10K
- Amarin Pharma, Inc.$8K
- Merck$3K
- Novo Nordisk$3K
- plus $7K from 19 others
Across 6 payments — averaging $7621.48 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$46K
What the payments were for
- Consulting fees$7,44512%
- Speaking & faculty fees$46,16772%
- Travel & lodging$4,8448%
- Food & beverage$5,8139%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi-aventis U.S. LLC | 13 | $19,036 |
| Regeneron Healthcare Solutions, Inc. | 17 | $13,458 |
| Siemens Medical Solutions USA, Inc. | 9 | $9,805 |
| Amarin Pharma, Inc. | 9 | $8,489 |
| Merck | 7 | $3,415 |
| Novo Nordisk | 3 | $3,243 |
| Boston Scientific | 10 | $1,585 |
| Medtronic | 18 | $1,379 |
| Abiomed | 5 | $690 |
| Fujifilm Sonosite, Inc. | 1 | $500 |
| AstraZeneca | 19 | $489 |
| Johnson & Johnson | 7 | $462 |
| Shockwave Medical, Inc | 4 | $419 |
| Novartis | 4 | $296 |
| Abbott | 2 | $282 |
| Pfizer | 7 | $263 |
| Portola Pharmaceuticals, LLC | 1 | $129 |
| E.r. Squibb & Sons, L.L.C. | 1 | $123 |
| Chiesi USA, Inc. | 2 | $53 |
| Bridgebio Pharma, Inc. | 1 | $35 |
| Stryker | 1 | $34 |
| Amgen | 1 | $24 |
| Heartflow, Inc. | 1 | $24 |
| Kestra Medical Technology Services, Inc. | 1 | $22 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- PRALUENT$31,750
- Vascepa$8,223
- VERQUVO$6,609
- RYBELSUS$3,188
- ACUSON Sequoia Diagnostic Ultrasound System$2,860
- ACUSON Origin Diagnostic Ultrasound System$2,040
- SC2000$1,640
- WATCHMAN Access System$1,281
- Resolute$918
- Sequoia$700
- Impella$540
- Software and Accessories$525
- PX Ultrasound System$500
- XARELTO$370
- ANDEXXA$254
- ENTRESTO$232
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$188
- AMPLATZER$184
- FARXIGA$125
- VYNDAQEL$105
How this compares
$64,269 in reported general payments places this provider in the 95th percentile of 370 cardiovascular disease providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 390 | $494,015 |
| XareltoRivaroxaban | 62 | $99,241 |
| Repatha SureclickEvolocumab | 71 | $80,507 |
| Praluent PenAlirocumab | 32 | $33,473 |
| EntrestoSacubitril/Valsartan | 20 | $31,335 |
| BrilintaTicagrelor | 11 | $13,092 |
| FarxigaDapagliflozin Propanediol | 14 | $7,840 |
| VascepaIcosapent Ethyl | 14 | $7,797 |
| Metoprolol Succinate | 495 | $7,214 |
| Rosuvastatin Calcium | 416 | $5,517 |
| Atorvastatin Calcium | 519 | $5,386 |
| Ezetimibe | 164 | $4,284 |
| ClopidogrelClopidogrel Bisulfate | 245 | $3,401 |
| Amlodipine Besylate | 336 | $3,217 |
| Losartan Potassium | 273 | $3,166 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $263 | $494,015390 claims |
| Johnson & JohnsonXarelto | $462 | $99,24162 claims |
| NovartisEntresto | $296 | $31,33520 claims |
| AstraZenecaBrilinta, Farxiga | $489 | $20,93225 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 370 cardiovascular disease providers in Washington.
Other cardiovascular disease in Bellevue
- Robert BersinBellevue$657K
- Eugene YangBellevue$31K
- Adam ZivinBellevue$23K
- Craig TuohyBellevue$5K
- Ryan YuanBellevue$5K
- Ronnier AvilesBellevue$5K
- James WatsonBellevue$5K
- Mariko HarperSeattle$246K
- Gary OppenheimSeattle$153K
- Kelley BranchSeattle$103K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.